German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs (Q38128726)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 August 2013

Language	Label	Description	Also known as
English	German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs	scientific article published on 14 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Ulf Müller-Ladner

27

object named as

Ulf Müller-Ladner

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Andrea Rubbert-Roth

21

object named as

Andrea Rubbert-Roth

0 references

Gerd-Rüdiger Burmester

10

object named as

Gerd R Burmester

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hans-Peter Tony

25

object named as

Hans-Peter Tony

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Christof Specker

23

object named as

Christof Specker

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Katinka Albrecht

1

object named as

Katinka Albrecht

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Siegfried Wassenberg

26

object named as

Siegfried Wassenberg

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hendrik Schulze-Koops

24

object named as

Hendrik Schulze-Koops

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

author name string

Klaus Krüger

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Jürgen Wollenhaupt

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Rieke Alten

4

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Marina Backhaus

5

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Christoph Baerwald

6

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Wolfgang Bolten

7

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Jürgen Braun

8

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Harald Burkhardt

9

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Markus Gaubitz

11

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Angela Gause

12

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Erika Gromnica-Ihle

13

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Herbert Kellner

14

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Jens Kuipers

15

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Andreas Krause

16

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hans-Martin Lorenz

17

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Bernhard Manger

18

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hubert Nüßlein

19

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Hans-Georg Pott

20

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Andrea Rubbert-Roth

21

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Matthias Schneider

22

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

German Society of Rheumatology

28

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Rheumatology International

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1-9

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year contin

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

New therapies for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2848-3

21 January 2018

Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23942828

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-013-2848-3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38128726&oldid=2201307765"